Corona Remedies Ltd. (Mainboard)

User profile picture

Corona Remedies

December 8, 2025 – December 10, 2025

Price ₹1008 - ₹1062
GMP Rumors * ₹330
Lot size 14
Issue size ₹655.37 cr
Allotment Dec 11, 2025
Listing Dec 15, 2025


Corona Remedies Lot(s) Distribution

Category Lot(s) Qty Amount Reserved
Retail 1 14 14868 152827
sHNI 14 196 208152 1559
bHNI 68 952 1011024 3119

Corona Remedies Reservation

Category Shares Offered %
QIB 3056533 49.53%
HNI 916960 14.86%
Retail 2139573 34.67%
Employee 58036 0.94%
Total 6171102 100%

Corona Remedies About

IPO Details
Total Issue Size6,171,102 shares (aggregating up to 655.37 Cr)
Offer for Sale6,171,102 shares (aggregating up to 655.37 Cr)
Issue TypeBookbuilding IPO
Listing AtNSE,BSE
Share Holding Pre Issue61,160,088 Equity Shares
Share Holding Post Issue61,160,088 Equity Shares
Key Performance Indicators
KPIJun-25Mar-25Mar-24
ROE7.61%27.50%20.36%
ROCE11.28%41.32%31.19%
RONW20.50%24.65%18.84%
EPS
(basic)
7.5524.4314.8
Financial Details In Crores
Period EndedJun-25Mar-25Mar-24Mar-23
Assets1,012.38929.86830.58595.02
Total Income348.561,202.351,020.93891.1
Profit After Tax46.2149.4390.584.93
EBITDA71.8245.91161.19135.03
NET Worth607.02606.34480.41408.52
Reserves and Surplus545.86545.18419.25347.36
Total Borrowing106.6562.7134.142.33
Company Overview
Founded: 2004

Sector: Indian Pharmaceutical Market (IPM)

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company engaged in the development, manufacturing, and marketing of products across key therapeutic categories, including women’s healthcare, cardiology, pain management, urology, and various multispecialty segments.

As of December 2024, the company’s product portfolio comprises 67 brands spanning women’s health, cardio-diabeto care, pain relief, urology, and multispecialty pharmaceuticals such as vitamins, minerals, nutrition, gastrointestinal, and respiratory products.

Corona Remedies has built a strong pan-India presence through a well-established marketing and distribution network. With 2,598 medical representatives across 22 states, the company maintains strong engagement with healthcare professionals and hospitals, driving deeper penetration in the Indian Pharmaceutical Market (IPM).

The company operates two manufacturing facilities located in Gujarat, supporting its production and quality-driven growth strategy.

Strength

Strong Market Growth Leadership: Second fastest-growing company among the top 30 pharma players (MAT 2022–2025), with strong positioning to capture India’s expanding pharma demand.

Diversified and Scalable Product Portfolio: Proven ability to build multiple “engine brands” across key therapies like women’s health, cardio-diabetic, pain, and urology, supporting sustainable long-term growth.

Robust Pan-India Sales Network: A wide national sales and marketing network focused on specialist doctors and mid-income patients, enabling higher prescription growth than the overall market.

Weakness

High Dependence on Few Therapy Areas: Over 60% of revenue comes from women’s health, cardio-diabetic, and pain management; underperformance or competition in these categories could impact growth.

Concentration in Limited Engine Brands: 27 key “engine brands” contribute over 70% of domestic sales; any decline in flagship brands like B-29 or Myoril could materially affect performance.

Heavy Reliance on Indian Market: More than 96% of revenue comes from India; weak domestic demand or slow international expansion could negatively affect financial stability.

Corona Remedies Address

Corona Remedies Ltd.
CORONA House, C – Mondeal Business Park
Near Gurudwara S. G. Highway
Thaltej
AhmedabadGujarat, 380059
Phone+91 79 4023 3000
Emailcomplianceofficer@coronaremedies.com
Website: https://www.coronaremedies.com/

Corona Remedies Registrar

Bigshare Services Pvt Ltd
Address: Bigshare Services Pvt Ltd 1st Floor, Bharat Tin Works Building, Opp. Vasant Oasis,Makwana Road, Marol, Andheri(E), Mumbai - 400 059

Corona Remedies Reviewers

Reviewer Recommendation File